Zortress Tablet
Product Images NDC 0078-0417

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Zortress (NDC 0078-0417). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Zortress Structural Formula Of Everolimus Is (1r, 9s, 12s, 15r, 16e, 18r, 19r, 21r, 23s, 24e, 26e, 28e, 30s, 32s, 35r)-1, 18-dihydroxy-12 -{(1r)-2-[(1s,3r,4r)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15, 17, 21, 23, 29, 35-hexamethyl-11, 36-dioxa-4-aza-tricyclo[30.3.1.04,9] Hexatriaconta-16,24,26,28-tetraene-2, 3,10,14,20-pentaone. (Zortress 01)

Chemical structure of everolimus, the active ingredient in Zortress tablets, illustrating the detailed molecular configuration.*

FDA Label Image

Principal Display Panelpackage Label – 0.25 mgrx Only Ndc 0078-0417-20zortress® (everolimus) Tablets (Zortress 02)

Packaging label for Zortress (everolimus) Tablets, 0.25 mg per tablet, oral dosage form. The label indicates the product contains six blister cards of 10 tablets each. Manufactured by Novartis Pharma Stein AG, Switzerland and distributed by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. The label includes dosage and storage instructions, a barcode, and regulatory information.*

FDA Label Image

Principal Display Panelpackage Label – 0.5 mgrx Only Ndc 0078-0414-20zortress® (everolimus) Tablets (Zortress 03)

Packaging label for Zortress (everolimus) Tablets 0.5 mg by Novartis Pharmaceuticals Corporation. The label shows the product name, active ingredient, strength, and dosage form. It includes dosage instructions referencing a package insert, storage conditions, and safety warnings. The label also details contents as 6 blister cards of 10 tablets each and includes manufacturer and distributor information.*

FDA Label Image

Principal Display Panelpackage Label – 0.75 mgrx Only Ndc 0078-0415-20zortress® (everolimus) Tablets (Zortress 04)

The packaging label for Zortress (everolimus) tablets displays the 0.75 mg per tablet strength. It indicates the product is an oral human prescription drug manufactured by Novartis Pharmaceuticals Corporation. The box contains 6 blister cards with 10 tablets each. The label includes storage instructions, a barcode, and contact information for medical advice and side effects reporting.*

FDA Label Image

Figure 1. Mean And 95% Ci Of Egfr (mdrd 4) [ml/min/1.73m2] By Visit Window And Treatment After Liver Transplantation (itt Population 24 Month Analysis)* (Zortress 05)

A line graph comparing eGFR (MDRD 4) values over time in two treatment groups: EVR+Reduced TAC and TAC Control. The x-axis represents visit windows from screening through 24 months, and the y-axis shows eGFR values in mL/min/1.73m². Error bars indicate variability in measurements.*

FDA Label Image

Zortress 06

Zortress (everolimus) Tablets 1 mg per tablet oral dosage form packaging label. The carton indicates contents of 8 blister cards with 10 tablets each, for a total of 80 tablets. Labeler is Novartis Pharmaceuticals Corporation, manufactured by Novartis Pharma Stein AG in Switzerland. The box includes storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.